Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade®, ICL670)

European Journal of Haematology

Volumn 78, Issue 6, 2007, Pages 540-542

  Di Tucci, Anna Angela ^a   Murru, Roberta ^a   Alberti, Daniele ^b   Rabault, Bertrand ^b   Deplano, Simona ^a   Angelucci, Emanuele ^a  

^a Ospedale Oncologico A Businco   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chelation; Iron overload; Myelofibrosis

Indexed keywords

DEFERASIROX;

ADULT; ANEMIA; ARTICLE; BLOOD SMEAR; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; COOMBS TEST; DRUG DOSE REDUCTION; ERYTHROCYTE CONCENTRATE; FEMALE; HUMAN; HUMAN TISSUE; IRON CHELATION; MYELOFIBROSIS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ANEMIA; BLOOD TRANSFUSION; DEFEROXAMINE; HUMANS; IRON CHELATING AGENTS; MYELOFIBROSIS;

EID: 34248594152     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00840.x     Document Type: Article

References (10)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France : IARC Press, 2001.
2. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996 88 : 1013 8.
3. Thiele J, Kvasnicka HM, Facchetti F, Franco V, Van Der Walt J, Orazi A. European consensus of grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005 90 : 1128 32.
4. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006 108 : 1497 503.
5. Jensen PD, Heickendorff L, Pedersen B, Bendix-Hansen K, Jensen FT, Christensen T, Boesen AM, Ellegaard J. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996 94 : 288 99.
6. Smeets ME, Vreugdenhil G, Holdrinet RS. Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol 1996 51 : 243 4.
7. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002 100 : 4272 90.
8. Louache F, Testa U, Pelicci P, Thomopoulos P, Titeux M, Rochant H. Regulation of transferrin receptors in human hematopoietic cell lines. J Biol Chem 1984 259 : 11576 82.
9. Vreugdenhil G, Smeets M, Feelders RA, Van Eijk HG. Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron-loading anaemia. Acta Haematol 1993 89 : 57 60.
10. Kontoghiorghes GJ, May A. Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells. Biol Met 1990 3 : 183 7.